SanBio Company Limited (SNBOY)

Market Cap	409.17M -64.8%
Revenue (ttm)	n/a
Net Income	-22.82M
EPS	-0.30
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	369
Open	5.51
Previous Close	6.07
Day's Range	5.51 - 5.51
52-Week Range	5.51 - 6.07
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 15, 2026

About SanBio Company

SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company’s research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to treat peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 33
• Stock Exchange: OTCMKTS
• Ticker Symbol: SNBOY

Financial Performance

Financial numbers in JPY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 9, 2026

Data Sources Report a data error